Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.37 |
| ▸ | GSR | P00390 | 2/20 | 0.37 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.37 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.37 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | GRM8 | O00222 | 1/20 | 0.37 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.37 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890461 | 1.00 | PTGS1 (0.39) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL5371555 | 0.92 | THRB (0.40) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL890551 | 0.86 | PTGS1 (0.42) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL890552 | 0.86 | PTGS1 (0.42) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL11243408 | 0.78 | GRB2 (0.40) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL18774923 | 0.77 | PTGS1 (0.42) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL15962510 | 0.77 | PTGS1 (0.42) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| Hydrochloric Acid SCHEMBL3905797 | 0.77 | NOS2 (0.40) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL76553 | 0.77 | PTGS1 (0.46) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 | |
| SCHEMBL4533762 | 0.77 | PTGS1 (0.46) | PTGS1SLC7A11SLC1A1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | claimed |
| US-20250171500-A1 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS | CALDER BIOSCIENCES INC (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250092094-A1 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS | CALDER BIOSCIENCES INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20240238369-A1 | Conformationally Specific Viral Immunogens | CALDER BIOSCIENCES INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-11993633-B2 | Conformationally stabilized RSV pre-fusion F proteins | CALDER BIOSCIENCES INC (US) | 2024-05-28 | — | — | US | disclosed |
| US-11926649-B2 | Conformationally stabilized RSV pre-fusion F proteins | CALDER BIOSCIENCES INC (US) | 2024-03-12 | — | — | US | disclosed |
| US-11752191-B2 | Conformationally-specific viral immunogens | CALDER BIOSCIENCES INC (US) | 2023-09-12 | — | — | US | disclosed |
| US-20230054569-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINITIS PIGMENTOSA | ALIA THERAPEUTICS SRL (IT) | 2023-02-23 | — | — | US | disclosed |
| US-20230053714-A1 | CONFORMATIONALLY STABILIZED RSV PRE-FUSION F PROTEINS | CALDER BIOSCIENCES INC (US) | 2023-02-23 | — | — | US | disclosed |
| EP-4077674-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINITIS PIGMENTOSA | Alia Therapeutics S.R.L. (IT) | 2022-10-26 | — | — | EP | disclosed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | disclosed |
| US-20020061549-A1 | Stabilized proteins | CALDER BIOSCIENCES INC. | 2002-05-23 | — | — | US | disclosed |
| EP-1196436-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001064678-A2 | INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001040262-A1 | ALPHA-KETOAMIDE INHIBITORS OF HEPATITIS C VIRUS NS3 PROTEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001029247-A1 | STABILIZED PROTEINS | AVATAR MEDICAL, LLC (US) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001002424-A2 | PEPTIDE BORONIC ACID INHIBITORS OF HEPATITIS C VIRUS PROTEASE | DU PONT PHARMACEUTICALS COMPANY (US) | 2001-01-11 | — | — | WO | disclosed |
| US-5658885-A | OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-19 | — | — | US | disclosed |
| EP-0787010-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-08-06 | — | — | EP | disclosed |
| WO-1996012499-A1 | AMIDINO AND GUANIDINO SUBSTITUTED INHIBITORS OF TRYPSIN-LIKE ENZYMES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | PTGS1 118/4885SLC7A11 2028/4885SLC1A1 2630/4885 |
| US-20230054569-A1 | COMPOSITIONS AND METHODS FOR TREATING RETINITIS PIGMENTOSA | RHOC, PDE6C, PDE6H | PTGS1 1969/4885SLC7A11 4322/4885SLC1A1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.